Search





Search





Liver drug developer Galectin Therapeutics' 2025 net loss narrows on reduced R&D costs

ReutersMar 31, 2026 12:09 PM

Overview

U.S. biotech's 2025 net loss narrowed as R&D expenses declined after NAVIGATE trial end
Company ended 2025 with $17.7 mln cash plus $10 mln credit line, extending runway to April 2027

Outlook

Company expects to fund planned operations and R&D activities through April 2027 with current cash and credit

Result Drivers

R&D COSTS DOWN - Net loss narrowed mainly due to lower research and development expenses after conclusion of NAVIGATE trial

Company press release: ID:nGNXXBl8B

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
FY EPS		-$0.48

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Tradingkey

Recommended Articles

Micron Plunges 10%, Earnings Beat Expectations, Stock Price Falls 30% Consecutively, Can AI Memory Chips Still Be Bought?

TradingKey — Micron Technology’s (MU) recent stock price performance has become a microcosm of shifting sentiment within the AI memory sector. Despite reporting robust earnings, the stock has weakened steadily following the announcement, marking a cumulative decline of nearly 30%. The market is now

IREN, NBIS, and CRWV: The Rise of Neoclouds in the AI Infrastructure Boom

Iris Energy (IREN), Nebius (NBIS) and Coreweave (CRWV) are frequently grouped due to their shared focus on AI infrastructure

Hedge Fund Tycoon Calls ‘Ten-Fold Opportunity,’ Fannie and Freddie Shares Both Surge Over 45%.

TradingKey - During Monday's U.S. Eastern trading session, shares of U.S. mortgage giants Fannie Mae and Freddie Mac experienced a rare surge, boosted by public bullish comments from renowned hedge fund manager Bill Ackman. Fannie Mae (FNMA) shares soared by more than 50%, while Freddie Mac (FMCC) jumped approximately 47%, becoming the focus of the market.

Bitcoin Price Analysis: What Is to Stop BTC from Making Another Run at All-Time Highs in 2026?

This strategic analysis covers institutional BTC price targets from JPMorgan and Fidelity, the impact of the U.S. Strategic Reserve, and whether the four-year cycle is broken. Stay updated on BTC to USD trends and key market risks.

Tesla (TSLA) 2026 Deep Dive Report: Behind the 5x Pricing Divergence, a Sunset Automaker or AI Giant?

An in-depth analysis of Tesla’s 2026 investment outlook, exploring the transformation into an AI giant and Robotaxi mass production plans behind Wall Street’s five-fold valuation gap. Through a comprehensive deconstruction of gross margin data, the energy business, and macro interest rate risks, we reveal the key investment signals and valuation reality for Tesla in 2026.

Tradingkey

KeyAI

